MPLT: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30
Net loss	-81,604
Depreciation	438
Stock-based compensation expense	485
Net amortization of premiums and accretion of discounts on investments	660
Common stock issued to neurosolis	496
Non-cash lease expense	644
Loss from disposal and write-off of equipment	-7
Prepaid expenses and other assets	10,774
Accounts payable	491
Accrued expenses	1,775
Operating lease liability	-573
Deferred grant earnings	-2,033
Net cash used in operating activities	-91,308
Purchases of short-term and long-term investments	142,057
Maturities of marketable debt securities	61,500
Purchases of property and equipment	97
Net cash used in investing activities	-80,654
Payments of deferred financing costs	1,127
Proceeds from issuance of series d redeemable convertible preferred stock, net of issuance costs	198,870
Proceeds from exercise of stock options	112
Net cash provided by financing activities	197,855
Increase (decrease) in cash, cash equivalents, and restricted cash	25,893
Cash and cash equivalents at beginning of period	38,460
Cash and cash equivalents at end of period	64,353

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

MPLT: the cashflow